Literature DB >> 10644358

Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells.

D L Lerner1, J H Elder.   

Abstract

A cytopathic variant of feline immunodeficiency virus (FIV) strain PPR emerged after passage of wild-type virus on an interleukin-2-independent cell line. The virus, termed FIV-PPRglial, displayed a phenotype markedly different from the parental virus, including the ability to productively infect previously refractory cell lines, induction of large syncytia, and accelerated kinetic properties. A chimeric molecular clone, FIV-PPRchim42, containing the FIV-PPRglial envelope within the backbone of FIV-PPR, exhibited all the characteristics of the FIV-PPRglial phenotype, demonstrating that the viral envelope was responsible for the acquired traits. Subsequent molecular characterization revealed that the FIV-PPRglial envelope contained five amino acid substitutions relative to wild-type FIV-PPR. Mutagenic analyses further demonstrated that the acquired phenotype was minimally attributable to a combination of three mutations, specifically, a glutamine-to-proline change within the second constant domain of the surface protein (SU); a threonine-to-proline change within the V4 loop, also in the SU; and a premature stop codon in the cytoplasmic tail of the transmembrane protein. All three changes were required to produce the FIV-PPRglial phenotype. Cotransfection studies with mutant viruses in combination with each other and with FIV-PPR indicated that the truncated cytoplasmic tail was responsible for the induction of syncytium formation. Receptor usage analyses were pursued, and distinctions were observed between FIV-PPR and FIV-PPRglial. In vitro infections with FIV-PPR, FIV-PPRglial, and FIV-34TF10 on two adherent cell lines were ablated in the presence of SDF1alpha, the natural ligand for CXCR4. In contrast, viral infection of T cells was not limited to CXCR4 usage, and inhibition studies indicate the potential involvement of a CC chemokine receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644358      PMCID: PMC111663          DOI: 10.1128/jvi.74.4.1854-1863.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Analysis of a human immunodeficiency virus type 1 isolate carrying a truncated transmembrane glycoprotein.

Authors:  H Shimizu; F Hasebe; H Tsuchie; S Morikawa; H Ushijima; T Kitamura
Journal:  Virology       Date:  1992-08       Impact factor: 3.616

2.  Growth of lion and puma lentiviruses in domestic cat cells and comparisons with FIV.

Authors:  S VandeWoude; S J O'Brien; K Langelier; W D Hardy; J P Slattery; E E Zuckerman; E A Hoover
Journal:  Virology       Date:  1997-06-23       Impact factor: 3.616

3.  Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity.

Authors:  J W Dubay; S J Roberts; B Brody; E Hunter
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein.

Authors:  C P Spies; R W Compans
Journal:  Virology       Date:  1994-08-15       Impact factor: 3.616

5.  Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein.

Authors:  J Cao; L Bergeron; E Helseth; M Thali; H Repke; J Sodroski
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

6.  Differences in feline immunodeficiency virus host cell range correlate with envelope fusogenic properties.

Authors:  G Pancino; S Castelot; P Sonigo
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

7.  A single mutation within the V3 envelope neutralization domain of feline immunodeficiency virus determines its tropism for CRFK cells.

Authors:  E J Verschoor; L A Boven; H Blaak; A L van Vliet; M C Horzinek; A de Ronde
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein.

Authors:  E O Freed; D J Myers
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

9.  A monoclonal antibody which blocks infection with feline immunodeficiency virus identifies a possible non-CD4 receptor.

Authors:  M J Hosie; B J Willett; T H Dunsford; O Jarrett; J C Neil
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated.

Authors:  C Yang; C P Spies; R W Compans
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

View more
  23 in total

1.  During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

Authors:  M Bendinelli; M Pistello; D Del Mauro; G Cammarota; F Maggi; A Leonildi; S Giannecchini; C Bergamini; D Matteucci
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Evolution of two amino acid positions governing broad neutralization resistance in a strain of feline immunodeficiency virus over 7 years of persistence in cats.

Authors:  Mauro Pistello; Donatella Matteucci; Simone Giannecchini; Francesca Bonci; Olimpia Sichi; Silvano Presciuttini; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

Review 3.  Lentiviral neuropathogenesis: comparative neuroinvasion, neurotropism, neurovirulence, and host neurosusceptibility.

Authors:  Megan K Patrick; James B Johnston; Christopher Power
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

4.  Experimental mucosal infection with molecularly cloned feline immunodeficiency viruses.

Authors:  Mariko Kohmoto; Yasuhiro Ikeda; Eiji Sato; Yorihiro Nishimura; Yasuo Inoshima; Masayuki Shimojima; Yukinobu Tohya; Takeshi Mikami; Takayuki Miyazawa
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

5.  Feline immunodeficiency virus Vif localizes to the nucleus.

Authors:  U Chatterji; C K Grant; J H Elder
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Binding of recombinant feline immunodeficiency virus surface glycoprotein to feline cells: role of CXCR4, cell-surface heparans, and an unidentified non-CXCR4 receptor.

Authors:  A de Parseval; J H Elder
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor.

Authors:  Aymeric de Parseval; Udayan Chatterji; Peiqing Sun; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

8.  Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators.

Authors:  Udayan Chatterji; Aymeric de Parseval; John H Elder
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Feline models of viral pathogenesis: opportunity knocks.

Authors:  Jennifer L Troyer; Meredith A Brown
Journal:  Vet J       Date:  2010-08-15       Impact factor: 2.688

10.  Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes.

Authors:  Samantha J McDonnel; Ellen E Sparger; Paul A Luciw; Brian G Murphy
Journal:  Virus Res       Date:  2012-10-13       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.